Literature DB >> 18853190

MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis.

Marco Checa1, Víctor Ruiz, Martha Montaño, Rafael Velázquez-Cruz, Moisés Selman, Annie Pardo.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic lung disorder of unknown etiology and unclear pathogenesis. Matrix metalloproteinase-1 (MMP-1) is strongly upregulated and may contribute to the abnormal remodeling that characterizes the disease. We conducted a case-control study of 130 IPF patients and 305 healthy controls to investigate associations between two polymorphisms of the MMP-1 gene promoter and IPF risk. First, using PCR-restriction fragment length polymorphism (PCR-RFLP) analysis we studied the 2G polymorphism at -1,607, shown previously to generate the core of an AP-1 binding site and correlate with high transcriptional activity and risk for IPF. The frequency of the 2G/2G genotype was higher in IPF than in controls (63 vs. 49%; P < 0.008; OR = 1.7; CI 1.15-2.79). Next, we studied a T/G SNP at position -755, which we identified by sequencing the MMP-1 promoter. Chromatin immunoprecipitation (ChIP) assay performed on IPF fibroblasts with either -755 genotype revealed an AP-1 binding site for TT(-755) and GT(-755) genotypes. The frequency of this SNP revealed no significant differences between IPF and healthy controls. However, when the study individuals were stratified by their smoking status, a significant increase in the T/T genotype frequency was observed in smoking cases compared with smoking controls (45 vs. 26%; P = 0.03; OR = 2.3; CI 1.15-4.97). These findings indicate that polymorphisms of the MMP-1 promoter may confer increased risk for IPF and reveal a putative gene-environment interaction between the -755 MMP-1 polymorphism and smoking in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853190     DOI: 10.1007/s00439-008-0571-z

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  24 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?

Authors:  M Selman; V Ruiz; S Cabrera; L Segura; R Ramírez; R Barrios; A Pardo
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-09       Impact factor: 5.464

Review 3.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.

Authors:  A L Katzenstein; J L Myers
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

4.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans.

Authors:  Fengrong Zuo; Naftali Kaminski; Elsie Eugui; John Allard; Zohar Yakhini; Amir Ben-Dor; Lance Lollini; David Morris; Yong Kim; Barbara DeLustro; Dean Sheppard; Annie Pardo; Moises Selman; Renu A Heller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

5.  A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility.

Authors:  Y Zhu; M R Spitz; L Lei; G B Mills; X Wu
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

Review 6.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

Review 7.  MMP-1: the elder of the family.

Authors:  Annie Pardo; Moisés Selman
Journal:  Int J Biochem Cell Biol       Date:  2005-02       Impact factor: 5.085

8.  Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Kevin Gibson; José Cisneros; Thomas J Richards; Yinke Yang; Carina Becerril; Samueal Yousem; Iliana Herrera; Victor Ruiz; Moisés Selman; Naftali Kaminski
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

9.  MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

10.  Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.

Authors:  Moisés Selman; Guillermo Carrillo; Andrea Estrada; Mayra Mejia; Carina Becerril; José Cisneros; Miguel Gaxiola; Rogelio Pérez-Padilla; Carmen Navarro; Thomas Richards; James Dauber; Talmadge E King; Annie Pardo; Naftali Kaminski
Journal:  PLoS One       Date:  2007-05-30       Impact factor: 3.240

View more
  30 in total

1.  Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.

Authors:  Sean P McGee; Hongmei Zhang; Wilfried Karmaus; Tara Sabo-Attwood
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

2.  Angiotensin-converting enzyme (ACE) gene polymorphisms are associated with idiopathic pulmonary fibrosis.

Authors:  Soo-Taek Uh; Tae-Hoon Kim; Eun-Young Shim; An-Soo Jang; Sung-Woo Park; Jong-Sook Park; Byung-Lae Park; Byoung Whui Choi; Hyoung Doo Shin; Dong Soon Kim; Choon-Sik Park
Journal:  Lung       Date:  2013-05-09       Impact factor: 2.584

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 4.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.

Authors:  Qiang Ding; Tracy Luckhardt; Louise Hecker; Yong Zhou; Gang Liu; Veena B Antony; Joao deAndrade; Victor J Thannickal
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 5.  Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.

Authors:  Vanessa J Craig; Li Zhang; James S Hagood; Caroline A Owen
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

Review 6.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

Review 7.  Personalized medicine: applying 'omics' to lung fibrosis.

Authors:  Jose D Herazo-Maya; Naftali Kaminski
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

8.  ADAM33 gene polymorphisms are associated with the risk of idiopathic pulmonary fibrosis.

Authors:  Soo-Taek Uh; An-Soo Jang; Sung-Woo Park; Jong-Sook Park; Chang-Gi Min; Yong Hoon Kim; Byung-Lae Park; Hyoung Doo Shin; Dong Soon Kim; Choon-Sik Park
Journal:  Lung       Date:  2014-04-13       Impact factor: 2.584

9.  CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells.

Authors:  Sarah M Eck; Anik L Côté; William D Winkelman; Constance E Brinckerhoff
Journal:  Mol Cancer Res       Date:  2009-07-07       Impact factor: 5.852

10.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.